Literature DB >> 20217132

Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer.

Birgitta Schlüter1, Roswitha Gerhards, Dirk Strumberg, Rudolf Voigtmann.   

Abstract

PURPOSE: Her2/neu protein overexpression and gene amplification is found in 20-30% of breast cancer patients and correlates with poor clinical outcome. Patients who profit from anti-Her2/neu- therapy are routinely selected by examination of tumour specimens using immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) separately. Many studies found a good correlation between both methods for score 1+ samples and for score 3+ samples, but not for score 2+ samples. In this study, we examined pleural and ascitic effusions with a combined approach using IHC and FISH on the same cells, under the following aspects: (1) frequency of Her2/neu protein expression and gene amplification in effusions; (2) correlation between score of protein expression and gene amplification; (3) impact of chromosome 17 polyploidy on Her2/neu protein expression.
METHODS: We examined 31 effusions from patients with breast cancer and 4 effusions from patients with ovarian cancer. Cytospins were analysed by IHC using two anti-Her2/neu antibodies and subsequently analysed by FISH with Her2/neu/CEP17 probes. Amplification was defined as: (1) Her2/neu gene copy number of more than 4 and (2) Her2/neu/CEP17 ratio of 2.0 or greater.
RESULTS: A system combining IHC and FISH was developed and 35 effusion specimens were examined. As much as 25 of them were scored as positive. All of them contained cells with heterogeneous scores. A total of 18 of the samples contained cells with scores that ranged from 0 to 3+. In the other samples scores ranged from 0 to 1+ or 0 to 2+. Cells were analysed for Her2/neu gene amplification and chromosome 17 ploidy with regard to their scores. As much as 15 of all samples had mean Her2/neu copy numbers of >4, but only 12% (n = 3) of the positive samples were amplified according to Her2/neu/CEP17 ratio. Only 22, 9% (n = 8) were polyploid (mean CEP17 > 4); but 65, 7% (n = 23) of all specimens contained single polyploid cells. In some cases up to 100% of the score 3+ cells showed chromosome 17 polyploidy. Here protein overexpression might be caused by polyploidy rather than by gene amplification. In some samples, we found single cells with gene amplification but without protein expression and cells without amplification but with protein overexpression.
CONCLUSION: The combination of IHC and FISH allows a differentiated analysis of single cells, which is especially important for effusions that are composed of heterogeneous cells. Therefore, cells with high gene amplification and/or protein overexpression can be detected and analysed even if their amount in the sample is small. Chromosome 17 polyploidy is important in some cases but this should be further examined on a larger series.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20217132     DOI: 10.1007/s00432-010-0790-2

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  55 in total

1.  Chromogenic in situ hybridization in tumor pathology.

Authors:  Jorma Isola; Minna Tanner
Journal:  Methods Mol Med       Date:  2004

2.  Simultaneous fluorescence immunophenotyping and interphase cytogenetics: a contribution to the characterization of tumor cells.

Authors:  K Weber-Matthiesen; M Winkemann; A Müller-Hermelink; B Schlegelberger; W Grote
Journal:  J Histochem Cytochem       Date:  1992-02       Impact factor: 2.479

3.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

Authors:  M J van de Vijver; J L Peterse; W J Mooi; P Wisman; J Lomans; O Dalesio; R Nusse
Journal:  N Engl J Med       Date:  1988-11-10       Impact factor: 91.245

4.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Authors:  Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

Review 5.  When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer.

Authors:  H Yamauchi; V Stearns; D F Hayes
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

6.  The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study.

Authors:  Erinn Downs-Kelly; Brian J Yoder; Mark Stoler; Raymond R Tubbs; Marek Skacel; Thomas Grogan; Patrick Roche; David G Hicks
Journal:  Am J Surg Pathol       Date:  2005-09       Impact factor: 6.394

7.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

8.  Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.

Authors:  M F Press; M C Pike; V R Chazin; G Hung; J A Udove; M Markowicz; J Danyluk; W Godolphin; M Sliwkowski; R Akita
Journal:  Cancer Res       Date:  1993-10-15       Impact factor: 12.701

9.  The effects of antibody clone and pretreatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literature.

Authors:  Patricia A Fetsch; Andrea Abati
Journal:  Diagn Cytopathol       Date:  2007-06       Impact factor: 1.582

Review 10.  Gene amplification and tumor progression.

Authors:  O Brison
Journal:  Biochim Biophys Acta       Date:  1993-05-25
View more
  7 in total

1.  Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer.

Authors:  An-Quan Shang; Jian Wu; Feng Bi; Yu-Jie Zhang; Lei-Rong Xu; Ling-Ling Li; Fei-Fei Chen; Wei-Wei Wang; Jian-Jun Zhu; You-Yi Liu
Journal:  Cancer Biol Ther       Date:  2017-04-27       Impact factor: 4.742

2.  High in-vivo stability in preclinical and first-in-human experiments with [18F]AlF-RESCA-MIRC213: a 18F-labeled nanobody as PET radiotracer for diagnosis of HER2-positive cancers.

Authors:  Xue Qin; Xiaoyi Guo; Tianyu Liu; Liqiang Li; Nina Zhou; Xiaopan Ma; Xiangxi Meng; Jiayue Liu; Hua Zhu; Bing Jia; Zhi Yang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-09-21       Impact factor: 10.057

Review 3.  Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer.

Authors:  Xianwen Hu; Dandan Li; Yujie Fu; Jiashen Zheng; Zelong Feng; Jiong Cai; Pan Wang
Journal:  Front Oncol       Date:  2022-06-15       Impact factor: 5.738

Review 4.  Lapatinib for the treatment of breast cancer in the People's Republic of China.

Authors:  Hongjiang Wang
Journal:  Onco Targets Ther       Date:  2014-07-31       Impact factor: 4.147

5.  The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies.

Authors:  Hui Luo; Xiaohui Xu; Miaomiao Ye; Bo Sheng; Xueqiong Zhu
Journal:  PLoS One       Date:  2018-01-30       Impact factor: 3.240

6.  A Novel, Personalized Drug-Screening System for Platinum-Resistant Ovarian Cancer Patients: A Preliminary Clinical Report.

Authors:  Yunke Huang; Jing Xu; Ke Li; Jing Wang; Yilin Dai; Yu Kang
Journal:  Cancer Manag Res       Date:  2021-03-29       Impact factor: 3.989

Review 7.  Molecular testing on serous effusion: An update.

Authors:  Saumya Sahu; Parikshaa Gupta; Pranab Dey
Journal:  Cytojournal       Date:  2021-12-06       Impact factor: 2.091

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.